3.39

8.13% -0.30

After Hours: 3.39

Terns Pharmaceuticals Inc (TERN)

Overview News Price History Option Chain Financials Discussions Forecast

Terns Pharmaceuticals Inc stock is traded at $3.39, with a volume of 1.42M. It is down -8.13% in the last 24 hours and down -22.43% over the past month. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Previous Close:

$3.69

Open:

$3.72

24h Volume:

1.42M

Relative Volume:

0.98

Market Cap:

$287.94M

Revenue:

Net Income/Loss:

$-95.90M

P/E Ratio:

-2.5682

EPS:

-1.32

Net Cash Flow:

$-79.09M

1W Performance:

-9.12%

1M Performance:

-22.43%

6M Performance:

-53.11%

1Y Performance:

-53.63%

1-Day Range:

$3.3105

$3.77

1-Week Range:

$3.3105

$3.98

52-Week Range:

$3.3105

$11.40

Terns Pharmaceuticals Inc Stock (TERN) Company Profile

Name

Terns Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (682)

Phone

650-525-5535 EXT.101

Address

1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TERN's Discussions on Twitter

Compare TERN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TERN Terns Pharmaceuticals Inc	3.39	287.94M	0	-95.90M	-79.09M	-1.32
VRTX Vertex Pharmaceuticals Inc	483.31	124.11B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	74.87B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.83B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.53B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	26.75B	3.30B	-501.07M	1.03B	-2.1146

Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform
Jun-22-23	Initiated	Mizuho	Buy
Jun-07-23	Initiated	Jefferies	Buy
May-31-23	Initiated	ROTH MKM	Buy
May-08-23	Initiated	BMO Capital Markets	Outperform
Feb-14-23	Initiated	JMP Securities	Mkt Outperform
Feb-07-23	Initiated	UBS	Buy
Sep-12-22	Initiated	H.C. Wainwright	Neutral
Sep-14-21	Resumed	Goldman	Buy
Mar-02-21	Initiated	Cowen	Outperform
Mar-02-21	Initiated	Goldman	Buy
Mar-02-21	Initiated	JP Morgan	Overweight

View All

Terns Pharmaceuticals Inc Stock (TERN) Latest News

10:28 AM

Terns Pharmaceuticals stock hits 52-week low at $3.54 - Investing.com India

10:28 AM

01:20 AM

Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30 - Defense World

01:20 AM

Mar 02, 2025

William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - Defense World

Mar 02, 2025

Feb 28, 2025

William Blair Initiates Terns Pharmaceuticals at Market Perform -February 28, 2025 at 08:12 am EST - Marketscreener.com

Feb 28, 2025

William Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform Recommendation - MSN

Feb 28, 2025

Feb 26, 2025

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Feb 26, 2025

Terns Pharmaceuticals reports progress in clinical trials By Investing.com - Investing.com Australia

Feb 26, 2025

New Terns Pharmaceuticals CFO Receives $2.8M Stock Option Package: What's Behind the Compensation? - StockTitan

Feb 26, 2025

Feb 25, 2025

Terns Pharmaceuticals reports progress in clinical trials - Investing.com India

Feb 25, 2025

Terns Pharmaceuticals Provides Program Updates and - GlobeNewswire

Feb 25, 2025

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th ... - The Bakersfield Californian

Feb 25, 2025

Can Terns Pharmaceuticals' $372M Cash Runway Fuel Its Promising CML and Obesity Pipeline? - StockTitan

Feb 25, 2025

Terns Pharmaceuticals Names Andrew Gengos as Chief Financial Officer -February 25, 2025 at 04:55 am EST - Marketscreener.com

Feb 25, 2025

Its CEO died. The company scrapped a promising program. Now, for their 2nd act. - PharmaVoice

Feb 25, 2025

Feb 24, 2025

Terns Pharmaceuticals appoints Andrew Gengos as CFO - TipRanks

Feb 24, 2025

Terns Pharmaceuticals Appoints Andrew Gengos as CFO - MSN

Feb 24, 2025

Terns Pharmaceuticals appoints new CFO to bolster growth By Investing.com - Investing.com Nigeria

Feb 24, 2025

Terns Pharmaceuticals appoints new CFO to bolster growth - Investing.com India

Feb 24, 2025

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer - The Manila Times

Feb 24, 2025

Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - StockTitan

Feb 24, 2025

Feb 22, 2025

Terns Pharmaceuticals stock hits 52-week low at $4 - Investing.com India

Feb 22, 2025

Feb 21, 2025

Terns Pharmaceuticals stock hits 52-week low at $4 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Oppenheimer Initiates Coverage of Terns Pharmaceuticals (TERN) with Outperform Recommendation - MSN

Feb 21, 2025

Feb 20, 2025

Terns Pharmaceuticals Appoints Robert Azelby to Board - TipRanks

Feb 20, 2025

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors - GlobeNewswire

Feb 20, 2025

Can This New Board Addition Transform Terns' Oncology Commercialization Strategy? - StockTitan

Feb 20, 2025

Savant Capital LLC Makes New $89,000 Investment in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Feb 20, 2025

Feb 15, 2025

Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN

Feb 15, 2025

Feb 14, 2025

Terns Pharmaceuticals stock hits 52-week low at $4.16 By Investing.com - Investing.com Canada

Feb 14, 2025

Feb 12, 2025

Bleakley Financial Group LLC Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Feb 12, 2025

Feb 11, 2025